NCT03184571 2025-09-25
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
BerGenBio ASA
Phase 2 Completed
BerGenBio ASA
BerGenBio ASA
BerGenBio ASA
University of Texas Southwestern Medical Center
GWT-TUD GmbH